Payment overview · 2025
General Payments
$303.80
23 reported records · 5 companies
Healthcare provider profile · identity verified
Ryan John Edwards, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · JENNINGS, LA · NPI 1619355252
Verified facts
What the public records show
CMS Open Payments records show Ryan John Edwards, M.D. received $303.80 in general payments during 2025 across 23 reported records.
ABBVIE INC. accounted for 50.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $153.34 | 50.5% | 14 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $64.42 | 21.2% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.20 | 12.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.39 | 10.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.45 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $303.80 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $117.60 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $92.62 | 8 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $64.42 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.20 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $9.55 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $4.76 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $4.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
148 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
171 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
81 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 248 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 231 | 74 |
| Gabapentin | Gabapentin | 224 | 53 |
| Atorvastatin Calcium | Atorvastatin Calcium | 207 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 190 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 184 | 46 |
| Lisinopril | Lisinopril | 178 | 40 |
| Mounjaro | Tirzepatide | 171 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 161 | 58 |
| Jardiance | Empagliflozin | 148 | 23 |
| Tramadol Hcl | Tramadol Hcl | 143 | 44 |
| Losartan Potassium | Losartan Potassium | 135 | 31 |
| Pregabalin | Pregabalin | 129 | 26 |
| Trazodone Hcl | Trazodone Hcl | 123 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 109 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 106 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 105 | 17 |
| Meloxicam | Meloxicam | 104 | 30 |
| Metformin Hcl Er | Metformin Hcl | 100 | 25 |
| Alprazolam | Alprazolam | 98 | 19 |
| Montelukast Sodium | Montelukast Sodium | 93 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 35 |
| Prednisone | Prednisone | 83 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 16 |
| Eliquis | Apixaban | 81 | suppressed |
| Furosemide | Furosemide | 81 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 19 |
| Buspirone Hcl | Buspirone Hcl | 79 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 79 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 26 |
| Metformin Hcl | Metformin Hcl | 77 | 20 |
| Omeprazole | Omeprazole | 77 | 19 |
| Ibuprofen | Ibuprofen | 76 | 20 |
| Potassium Chloride | Potassium Chloride | 75 | 13 |
| Famotidine | Famotidine | 71 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 69 | 16 |
| Xarelto | Rivaroxaban | 69 | suppressed |
| Ozempic | Semaglutide | 68 | 11 |
| Carvedilol | Carvedilol | 66 | 19 |
| Sertraline Hcl | Sertraline Hcl | 57 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 22 |
| Allopurinol | Allopurinol | 51 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 51 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 50 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 14 |
| Torsemide | Torsemide | 48 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | suppressed |
| Mirtazapine | Mirtazapine | 47 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 12 |
| Finasteride | Finasteride | 41 | 11 |
| Simvastatin | Simvastatin | 41 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 39 | suppressed |
| Clonazepam | Clonazepam | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Rybelsus | Semaglutide | 34 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 22 |
| Glimepiride | Glimepiride | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Ibu | Ibuprofen | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 15 |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Gemtesa | Vibegron | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 13 |
| Nitroglycerin | Nitroglycerin | 17 | 12 |
| Nurtec Odt | Rimegepant Sulfate | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Permethrin | Permethrin | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $303.80 · 23 records | ABBVIE INC. | AIRSUPRA, BREZTRI, CREON, NURTEC ODT, QULIPTA, Qelbree, UBRELVY, VIBERZI, VRAYLAR, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error